University of Wisconsin–Madison Medical College of Wisconsin

Reactive Infectious Mucocutaneous Eruptions (RIME) in COVID-19

Rabeea Farhan, MBBS; Shaharyar Salim, MBBS; Asif Surani, MD

WMJ. 2023;122(5):368-371

Download full-text pdf


Reactive infectious mucocutaneous eruptions (RIME) is a relatively novel terminology describing postinfectious mucocutaneous eruptions that usually affect 2 or more mucosal sites. To our knowledge, we describe the first case of RIME secondary to COVID-19 infection in an elderly 64-year-old immunocompetent male patient. This contrasts with previous case reports that have identified cases of RIME post-COVID-19 infection among the pediatric population and young adults. Our patient had characteristic mucosal involvement and required hospitalization and treatment with systemic steroids. This report also reviews the clinical features, treatment modalities, and outcome of RIME secondary to COVID-19 infection in other published case reports. We emphasize the need for further prospective studies to better elucidate the use of steroids in the management of RIME.

Author Affiliations: St. Luke’s Warren Hospital, Phillipsburg, New Jersey (Farhan); Aga Khan University Medical College, Karachi, Pakistan (Salim); Department of General Internal Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin (Surani).
Corresponding Author: Shaharyar Salim, MBBS, Aga Khan University Medical College, Karachi, Pakistan 1922, Edenwold Heights, NW, Calgary Alberta, Canada; phone +18258631995; email; ORCID ID 0000-0002-2168-0418
Funding/Support: None declared.
Financial Disclosures: None declared.
Acknowledgements: The patient granted consent for publication of this case report and the use of photos.
Share WMJ